CARLSBAD, Calif., Aug. 27, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the first end-to-end sequencing solution for exon-level copy number variation (CNV) analysis, which combines the Ion Reporter™ CNV data analysis workflow, the Ion AmpliSeq™ Exome Kit and the Ion Proton® System.
Inherited and de novo CNVs of chromosomal regions, in which large regions (>1 kb of the genome) are duplicated or deleted, are associated with many diseases, including cancer, autism, and schizophrenia. Until now, the primary CNV analysis methods—microarrays and fluorescence in situ hybridization—have had poor dynamic range, limited breakpoint resolution, lower genomic coverage, and can only detect known single nucleotide polymorphisms (SNPs).
"The launch of the industry's first solution for whole human exome CNV analysis using Ion AmpliSeq™ Exome is another example of how Ion Torrent is delivering turnkey solutions to enable sequencing for all," said Ion Torrent's Vice President of Marketing, Maneesh Jain. "The Ion AmpliSeq™ Exome Kit and Ion Reporter™ Software provide an integrated solution for detecting SNPs, indels and high-resolution copy number variation."
The Ion Reporter™ Software CNV data analysis workflow vastly simplifies and automates all of the steps for a priori identification and interpretation of CNVs, SNPs, and indels so virtually anyone can quickly understand the implications of their exome data with the same sensitivity as microarray data. Simply choose the predefined Ion Reporter™ Software CNV data analysis workflow, run the sample and receive a list of mutations, including copy number variants ranging in size from exon level up to aneuploidies, and associated annotations drawn from dozens of public databases—all in a single day.
The Ion AmpliSeq™ Exome Kit and Ion Proton® Sequencer are For Research Use Only. Not for use in diagnostic procedures.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum—scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
SOURCE Life Technologies Corporation